Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
J. Kleinehr, K. Daniel, F. Günl…·E. R. Hrincius
This paper shows that inhibiting glycolysis with 2-DG reduces influenza A virus replication by impairing the viral polymerase's transition from transcription to replication.
J. Schuhenn, T. L. Meister, D. Todt…·S. Pfaender
The paper identifies differential antiviral effects of IFN-alpha subtypes against SARS-CoV-2 and highlights IFN5's superior activity, suggesting therapeutic potential.
S. Schloer, L. Brunotte, J. Goretzko…·U. Rescher
This study identifies fluoxetine and other FIASMAs as inhibitors of SARS-CoV-2 entry by targeting endolysosomal acidification and cholesterol accumulation.
U. Rescher, S. Schloer, L. Brunotte…·S. Ludwig
This study evaluates the antiviral effects of combining remdesivir with repurposed drugs fluoxetine and itraconazole, showing >90% inhibition of SARS-CoV-2 particle production in vitro.
M. Z. Chaudhry, K. Eschke, M. Hoffmann…·L. Cicin-Sain
This study shows SARS-CoV-2 adapts to Vero E6 cells by losing the furin cleavage motif in spike protein, but retains wildtype sequences, enabling reverse adaptation when passaged on human lung cells.
F. Bertoglio, D. Meier, N. Langreder…·M. Hust
The paper identifies potent SARS-CoV-2 neutralizing antibodies from pre-pandemic human donors that bind the RBD-ACE2 interface, showing high neutralization efficacy in vitro.